Cambridge Healthtech Institute’s 7th Annual

Combination Cancer Immunotherapy

Rational Combination Strategies to Improve Efficacy and Reduce Resistance

August 5-6, 2019



The future of immuno-oncology drug development is positioned in combination therapies, where immunotherapy modalities are tested in rational combinations with other immunotherapies or targeted therapies for synergistic effects. Combination immunotherapy promises to deliver long-term survival benefits that may be unavailable with current approaches. The Seventh Annual Combination Cancer Immunotherapy conference will explore the most effective combinations of immunotherapy with conventional cancer therapy, with other immunotherapy or with targeted therapy. Coverage will include understanding the mechanism of action, managing toxicity, strategies to design synergistic combinations, biomarker development and case studies of ongoing combination immunotherapy studies from the leading researchers in industry and academia. 

COMBINING IMMUNOTHERAPY MODALITIES OR OTHER CANCER THERAPIES

Cooperative Immune-Mediated Mechanisms of the HDAC Inhibitor Entinostat, an IL-15 Superagonist, and a Therapeutic Cancer Vaccine
Sofia Gameiro, PharmD, PhD, Head, Immunomodulation Group, Laboratory of Tumor Immunology and Biology, NCI, NIH

Immunocytikines: Sending the Right Signals in Immune-Based Combinations
Ravi Madan, MD, Clinical Director, Genitourinary Malignancies Branch, National Cancer Institute

Why Are We So Late in Treatment of Breast Cancer Using ICI?
Stefan Glueck, MD, PhD, FRCPC, Professor of Medicine, Vice President, GMA Early Assets, Celgene Corporation

COMBINATION STRATEGIES TO INCREASE RESPONSE TO CHECKPOINT MODULATORS

Induction of Durable Regression in PD-1 Refractory Melanoma Following Intratumoral Injection of a CpG-A TLR9 Agonist, CMP-001 in Combination with Systemic Pembrolizumab
Arthur Krieg, MD, Founder & CSO, Checkmate Pharmaceuticals

Immunotherapy Combinations: Lessons Learned and Future Outlook
Maria Karasarides, PhD, Executive Director, Immuno-Oncology Global Development, Regeneron Pharmaceuticals

Combination of NKTR-214 and Opdivo
Wei Lin, PhD, Senior Vice President, Oncology Development, Nektar Therapeutics

BIOMARKERS TO GUIDE COMBINATION IMMUNOTHERAPY

TMB/GEP Dual Biomarker Strategy for Personalized Checkpoint Blockade Combination Immunotherapy
Jianda Yuan, MD, PhD, Senior Director, Translational Oncology, Merck

Possible Use of Immunoprofiling to Stratify or Direct Combination Immunotherapy
Bernard A. Fox, PhD, Chief, Laboratory of Molecular and Tumor Immunology, Providence Health & Services; CEO, UbiVac


For more details on the conference, please contact:
Julia Boguslavsky
Executive Director, Conferences
Cambridge Healthtech Institute
Email: juliab@healthtech.com

For partnering and sponsorship information, please contact:
Rod Eymael
Manager, Business Development
Cambridge Healthtech Institute
Phone: (+1) 781-247-6286
Email: reymael@healthtech.com



Connect With Us

MEETING SUGGESTIONS

For meeting questions or suggestions, please contact:

Julia Boguslavsky
Executive Director, Conferences
Cambridge Healthtech Institute
juliab@healthtech.com

PARTNERING & SPONSORSHIP

For partnering and sponsorship info, please contact:

Rod Eymael
Manager, Business Development
Cambridge Healthtech Institute
+1 781.247.6286
reymael@healthtech.com

MEDIA & ASSOCIATION

For media and association partnerships, please contact:

Pete DeOlympio
Sr. Marketing Manager
Cambridge Healthtech Institute
+1 781.972.5415
peted@healthtech.com